Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > More now, than before Trogarzo FDA nod

<< Previous

Bullboard Posts

Next >>

Post by FredTheVoiceon Jan 21, 2021 10:37am

174 Views

Post# 32344386

More now, than before Trogarzo FDA nod

I bought more this morning,

I am more invested now in TH than before approval of Trogarzo.

Confidence, despite general bashing (market, and reaction after financing), is in my view higher today with two studies who will create lots of excitment around this company.

In a year or so, and maybe much faster with the oncology study, I think no one will be thinking about the january 2021 financing. With the attention around the financing, we all forgot that sales are gaining momentum......

GLTA.

FTV.

<< Previous

Bullboard Posts

Next >>

Immigration technology stock CanPR begins trading on the TSXV